Bruker Daltonics Introduces Esquire HCT with UltraScan, a Novel High Capacity Trap for Faster, Even More Sensitive Bioanalysis.Business Editors/Health/Medical Writers Pittcon 2003 BIOWIRE2K ORLANDO, Fla.--(BUSINESS WIRE)--March 10, 2003 New Esquire HCT Hct abbr. hematocrit HCT Hematocrit, see there is ten times more sensitive and features 26 kDa/sec UltraScan At PittCon 2003, Bruker Daltonics Bruker Daltonics is a global scientific instrument manufacturer. The company is a part of Bruker Biosciences Corporation (Nasdaq:BRKR) and specializes in mass spectrometry. The Bruker Daltonics headquarters are in Billerica, MA - USA and Bremen, Germany. Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BDAL BDAL Battle Doll Angelic Layer (game) ) today introduces the esquire HCT(TM), a novel ultra-high performance ion trap mass spectrometer for dramatically faster and more sensitive analysis in proteomics and metabolomics. This next-generation high capacity trap (HCT) combines substantially higher ion storage capacity with a proprietary ultrahigh-performance scan mode for the ultimate in ion trap research performance. Specifically, in addition to greatly increased storage capacity for ions, the esquire HCT features the breakthrough UltraScan(TM) mode for 26,000 Dalton/second analysis, while retaining better than unit mass resolution. The UltraScan is thus 5-6 times faster than other older-generation ion traps or recent triple-quadrupole derived so-called "linear" traps. The esquire HCT also offers a unique fast PeptideScan(TM) mode that can differentiate doubly and triple charged peptides in proteomic analysis over the entire mass range, again at scan speeds that dramatically exceed other types of ion traps. The HCT high capacity trap together with the UltraScan bring full m/z-scan ion trap sensitivities for metabolites Metabolites Substances produced by metabolism or by a metabolic process. Mentioned in: Interactions into the sub-picogram level for the first time, an order of magnitude A change in quantity or volume as measured by the decimal point. For example, from tens to hundreds is one order of magnitude. Tens to thousands is two orders of magnitude; tens to millions is three orders of magnitude, etc. sensitivity improvement compared to existing ion traps. The sensitivity for proteomics is expected to reach the low to mid attomole range for many proteins, an order of magnitude improvement. The esquire HCT is unique due to its standard m/z-range up to 3,000 Dalton, a very desirable feature for proteomics, and a necessity for API-MALDI ion trap mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. . The extended mass range scan can even reach up to 6,000 Dalton. The new ultra-high performance esquire HCT, priced at $225,000, extends Bruker Daltonics' esquire ion trap mass spectrometry product line, which already includes the existing high-end research-grade esquire3000plus, as well as the more routine esquire2000 bioanalytical LC/MS/MS system. The new esquire HCT can be fully integrated into the Proteineer(TM) proteomics suite, combining automated sample preparation systems, advanced mass spectrometry and bioinformatics. Frank H. Laukien, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , commented: "The esquire HCT represents a breakthrough in ion trap capabilities. We expect that in most performance aspects that matter to mass spectrometrists who perform proteomics or small-molecule structural analysis, it will outperform, in many cases very significantly, existing technologies and products. We are confident that the esquire HCT will be well received by demanding research customers." ABOUT BRUKER DALTONICS Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com or www.bdal.de CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion